Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $135.1 million.

  • Vanda Pharmaceuticals' Total Liabilities rose 3007.84% to $135.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.1 million, marking a year-over-year increase of 3007.84%. This contributed to the annual value of $117.7 million for FY2024, which is 1364.63% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Total Liabilities stood at $135.1 million, which was up 3007.84% from $138.4 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Total Liabilities peaked at $138.4 million during Q2 2025, and registered a low of $75.6 million during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $103.9 million (2024), whereas its average is $105.2 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Total Liabilities skyrocketed by 3423.72% in 2022, and later crashed by 718.55% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Total Liabilities (Quarter) stood at $88.9 million in 2021, then rose by 20.46% to $107.0 million in 2022, then dropped by 3.29% to $103.5 million in 2023, then rose by 13.65% to $117.7 million in 2024, then rose by 14.86% to $135.1 million in 2025.
  • Its last three reported values are $135.1 million in Q3 2025, $138.4 million for Q2 2025, and $120.5 million during Q1 2025.